STOCKUPSIDE.IO
Analyst Price Target Intelligence
← Full Rankings
← Back to rankings
Ranked #1759 by analyst upside · 2026-08-13
AXSM
Axsome Therapeutics, Inc.
Healthcare · Market Cap $11B · P/E 0x
ANALYST PRICE TARGET
+32.3%
implied upside to consensus target
Current Price $214.66
Consensus Target $283.9
Bull Target $380.0
Bear Target $246.0
Analysts Covering 21
ANALYST CONSENSUS - BUY
Strong Buy
3
Buy
17
Hold
1
Sell
0
52-Week Low $104.15
52-Week High $260.19
YTD Return +20.1%
FUNDAMENTALS
Market Cap $11B
P/E Ratio (TTM) N/A
Forward P/E 42.2x
EPS (TTM) $-3.74
PEG Ratio N/A
Dividend Yield N/A
Revenue (TTM) $777M
Profit Margin -24.7%
52-WEEK RANGE
52-Week Low $104.15
52-Week High $260.19
Current Price $214.66
Bear Target $246.0
Bull Target $380.0
● Now $214.66 ● Target $283.9
TRADING DATA
Avg Volume 865K
YTD Return +20.1%
Analyst Count 21
Consensus Buy
Upside to Target +32.3%
Last Updated 2026-08-13

ANALYST SUMMARY

Axsome Therapeutics, Inc. (AXSM) is currently trading at $214.66 with a Wall Street consensus price target of $283.9, implying potential upside of 32.3% over the next 12 months. 21 analysts currently cover AXSM, with a consensus rating of Buy - 95% of analysts rate the stock a Buy or Strong Buy. The most bullish analyst has a price target of $380.0, while the most cautious has a target of $246.0.

AXSM operates in the Healthcare sector with a market capitalisation of $11B. The stock is up 20.1% year-to-date and is currently trading near the upper end of its 52-week range of $104.15 – $260.19.

SIMILAR STOCKS

Other Healthcare stocks with comparable size and valuation.

RECENT ANALYST CALLS

Upgrade/downgrade history for AXSM, with each firm's 90-day track record across all stocks we track. See full firm rankings →

TD Cowen - Reiterated
Buy → Buy 2026-06-17 Building track record
Morgan Stanley - Reiterated
Equal-Weight → Equal-Weight 2026-05-05 Building track record
RBC Capital - Reiterated
Outperform → Outperform 2026-05-05 Building track record
Wells Fargo - Reiterated
Overweight → Overweight 2026-05-05 Building track record
Guggenheim - Reiterated
Buy → Buy 2026-05-05 62% win rate (8 calls)
Mizuho - Reiterated
Outperform → Outperform 2026-05-05 Building track record
Baird - Reiterated
Outperform → Outperform 2026-05-05 Building track record
HC Wainwright & Co. - Reiterated
Buy → Buy 2026-05-05 31% win rate (48 calls)
HISTORICAL SNAPSHOT

Point-in-time data from StockUpside's daily snapshots. Tracks price, analyst target, upside %, consensus, and analyst count.

Loading…
ANALYST CONVICTION SCORE
64
out of 100
Coverage depth
24/30
Consensus clarity
18/30
Vote unanimity
20/25
Rating stability
2/15

Measures analyst agreement, not fundamental quality. A high score means analysts broadly agree on this call - not that the stock will go up.

See 4,000+ stocks ranked by analyst upside

StockUpside.io tracks analyst consensus price targets across thousands of US-listed stocks, updated every day. The full ranked list is available with a Pro subscription.

View Full Rankings →